Osteoporosis is a common bone disease inflicting about 40% of women and 12% of men at some point during life. 1 It is mainly characterized by the unbalanced loss of bone mass with decreased density and deteriorated bone microarchitecture, leading to osteoporotic fracture. The social economic burden of osteoporosis is so large that its etiology, prevention and treatment have become an urgent issue that needs to be coped with worldwide.
It is generally believed that many genetic and environmental factors and the ways in which they interact with each other underlie the development of osteoporosis. 2 However, the exact genetic pathogenesis remains unclear although a large number of candidate genes and their proteins are known to be involved in bone metabolism. 3 Anti-osteoporotic pharmacotherapies mainly involve supplements of vitamin D and calcium along with independent or combined use of drugs like hormones, selective estrogen receptor modulators (eg tamoxifen, raloxifene), bisphosphonates (eg alendronate, risedronate) and calcitonin. 4 However, the efficacy of antiosteoporotic treatments may vary significantly among individuals. This fact encourages the application of pharmacogenetic approaches to osteoporosis research, with the aim of dissecting the genetic contribution to interindividual difference in drug response. By means of the population-based association method, several major candidate genes, such as vitamin D receptor (VDR), estrogen receptor alpha (ER-a) and collagen I alpha 1 (COLIA1) genes, have been investigated with regard to osteoporosis drug responses.
The major biological function of VDR is to mediate the multiple and complex actions of 1,25-(OH) 2 vitamin D, including its effect on calcium transport and homeostasis and bone resorption. Many association studies have been conducted on the relationship between various bone phenotypes and VDR gene polymorphisms, such as the VDR BsmI and TaqI polymorphisms. Based on the summarized data, Liu et al 5 tentatively concluded that bb or TT genotypes were more advantageous in terms of bone metabolism, calcium homeostasis, bone accrual during childhood and bone retention later in life, while BB or tt individuals might be more likely to develop osteoporosis. Data from some pharmacogenetic studies provided some support. In the Framingham study cohort, dietary calcium intake was positively associated with BMD only among those with the bb genotype. 6 In a sample of 60 postmenopausal women, the calcium absorption efficiency on low calcium intake was significantly lower in subjects with BB genotype than those with bb genotype. 7 Matsuyama et al 8 also reported that the bb genotype was associated with a greater increase in BMD in response to the vitamin D supplementation in Japanese. Furthermore, it was reported in a Japanese study that the TT homozygotes benefited from HRT more than the Tt heterozygotes. 9 However, the opposite or 'no association' conclusions were made in other studies. [10] [11] [12] [13] [14] These discrepancies may be accounted for by many confounding variables such as population admixture, epistasis, gene Â environment interaction, linkage disequilibrium and allele or locus heterogeneity across different populations. Further studies with robust study designs are needed for a better understanding of the relationship between the VDR polymorphisms and the efficacy of anti-osteoporotic therapies.
Pharmacogenetic studies of the ER-a gene mainly involve two marker loci, the XbaI and PvuII polymorphisms. Deng et al 15 reported a positive association between the XX homozygotes and the increase of spine BMD in response to HRT treatment in postmenopausal Caucasian women. As for the PvuII polymorphism, the study of a cohort of Finnish perimenopausal women showed that the P allele was significantly associated with the reduction in the incidence of new fractures in the group treated with HRT. But in the non-HRT group, the PvuII polymorphism was not significantly associated with fracture risk. 16 This result suggests that the gene Â drug interaction may have an influence on the results of association studies, which might be one of the confounding factors underlying the outcome of osteoporosis research. Ongphiphadhanakul et al 17 also found that the increase in vertebral BMD responding to estrogen therapy was significantly lower in Thai postmenopausal women without the P allele compared to those with the P allele, which partially supported Salmen et al's conclusion. 16 In addition, BMD changes after HRT were reported to be associated with another polymorph-ism in the ER-a gene, a T262C transition in exon 1, which may be in linkage disequilibrium with the PvuII polymorphism. 18 However, no significant difference in BMD change was observed between different genotypes of either PvuII or XbaI polymorphisms after treatment with selective estrogen receptor modulators. 19 For the COLIA1 gene, the Sp1 polymorphism was often studied. Cultured osteoblasts from 'Ss' heterozygotes produced increased amount of the collagen a1(I) chain because the s allele had greater affinity for transcription factor Sp1 than did the S allele. The resulted overproduction of a1(I) 3 in collagen may be responsible for impaired bone strength. 20 In agreement with this theory, many studies showed the association between the Sp1 polymorphism and the risk for osteoporosis or fractures. 5 Although inconsistent association results exist, two meta-analyses 21, 22 supported that the presence of the s allele was significantly associated with low BMD and fracture prevalence though such effect on bone metabolism was moderate and could be easily modified by environmental factors. In keeping with this, one pharmacogenetic research demonstrated that the s allele negatively influences BMD response to the etidronate therapy since femoral neck BMD obviously increased in the SS group while decreased in the Ss/ss group. 20 This finding also implied the possible clinical value of using COLIA1 Sp1 polymorphism in targeting etidronate therapy to patients who are most likely to respond, with potential advantages in terms of cost and clinical outcome.
Traditional association studies frequently analyze one marker independently of other markers. Haplotypes reconstructed by multiple markers in a gene are usually more informative due to the existence of accumulated allelic effects at different loci and/or interactions between these loci. 23 In the osteoporosis research field, although few haplotype analyses were done in the pharmacogenetic context, some haplotypes of certain candidate genes were already studied and associated with bone phenotypes. 5 Moreover, the underway 'HapMap' project 24 holds promise for the genome-wide association studies that will use haplotype blocks to unravel some mystery of osteoporosis and provide an ideal regimen of treatment for osteoporotic patients according to the complete genetic evaluations. Yet, a large number of SNPs will be required for such whole genome association studies. Other limitations exist as well, such as the availability of large patient populations, the high price of genotyping and the extent and distribution of linkage disequilibrium (LD) in the human genome. Therefore, the candidate gene approach is still the most feasible method in the genetic and pharmacogenomic studies of osteoporosis at present.
Linkage analysis was another prevalent approach to the osteoporosis genetic research. Our recent review systematically tabulated the chromosome regions, showing evidence of linkage with osteoporosis-related phenotypes. 5 Some of them (2p23-24, 1p36, 3q21, 4q31 and 13q34) were replicated to be linked with BMD phenotype, but no region was completely confirmed. However, no genome-wide linkage scan for loci influencing the efficacy of anti-osteoporotic therapies was launched. Such studies may be only performed in animals because it is almost impossible to administer a given drug to multiple family members of mankind.
Pharmacogenomic approaches to osteoporosis are just in their infancy. They should be further developed and combined with other functional genomic approaches to be more powerful in the genetic dissection of osteoporosis. Functional genomics broadly includes a set of technologies and strategies focused on finding the function of genes and understanding how the genome works together to generate whole patterns of biological function. 25 Currently, DNA microarrays may be the most powerful of the techniques that address global functional genomics questions. The goal of analyzing the expression of thousands of genes can be achieved in a single experiment using DNA microarrays. Thus, the study of global gene expression patterns that are affected in symphony by specific diseases and drug treatments can be greatly facilitated. Moreover, DNA microarrays can be used for drug target validation and disease diagnoses. In a recent review, it was also shown that microarrays could be employed to identify molecular subtypes of given disease traits to help find the genetic loci specific to each subtype. 26 Such an application may provide an alternative way to identify genes underlying osteoporosis. 27 Yet, the DNA microarrays approach is not perfect since it only aims at the level of RNA alterations. A complementary approach is proteomics, which is the analysis of global changes in protein expression. It deals with changes that DNA microarrays cannot target, which include protein abundance, protein-protein interactions and post-translational modifications. 25 Now the proteomics approach is being applied to the discovery of new drug targets and the study of drug response, thus leading to the birth of pharmacoproteomics. The judicious use of genetic epidemiology, DNA microarrays and/or proteomics techniques in the osteoporosis research can complement pharmacogenomic methods for the better understanding of osteoporosis.
Pharmacogenomic approaches will have a significant impact on the treatment of osteoporosis. It can help map new anti-osteoporotic drug targets, improve the efficiency of drug development and move from 'one drug fits all' to personalized therapy. In this way, significant cost savings within the healthcare system can be produced and the risk of serious side effects reduced as well.
